A5101637615- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- Multiple Myeloma Research and Treatments
- Cancer survivorship and care
- Cancer Genomics and Diagnostics
- Erythropoietin and Anemia Treatment
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Childhood Cancer Survivors' Quality of Life
- Iron Metabolism and Disorders
- Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Commutative Algebra and Its Applications
- BRCA gene mutations in cancer
- Head and Neck Cancer Studies
- Biosimilars and Bioanalytical Methods
- Multiple and Secondary Primary Cancers
- Cancer-related Molecular Pathways
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Economic and Financial Impacts of Cancer
- Breast Lesions and Carcinomas
Complejo Hospitalario de Salamanca
2010-2024
Icahn School of Medicine at Mount Sinai
2024
GEICAM – Spanish Breast Cancer Group
2012-2024
Instituto de Investigación Biomédica de Salamanca
2015-2024
Universidad de Salamanca
2004-2024
Mount Sinai Hospital
2024
Hospital Clínico San Carlos
2024
Centro de Investigación del Cáncer
2005-2021
Universidad de Las Palmas de Gran Canaria
1997-2016
Hospital Universitario Ramón y Cajal
2013-2015
Depression is common in later life.To determine whether exercise effective as an adjunct to antidepressant therapy reducing depressive symptoms older people.Patients were randomised attend either classes or health education talks for 10 weeks. Assessments made "blind" at baseline, and 34 The primary outcome was seen with the 17-item Hamilton Rating Scale (HRSD). Secondary outcomes Geriatric Scale, Clinical Global Impression Patient Impression.At weeks a significantly higher proportion of...
Taxanes are among the most active drugs for treatment of metastatic breast cancer, and, as a consequence, they have also been studied in adjuvant setting. After cancer surgery, women with lymph node–positive disease were randomly assigned to fluorouracil, epirubicin, and cyclophosphamide (FEC) or FEC followed by weekly paclitaxel (FEC-P). The primary endpoint study—5-year disease-free survival (DFS)—was assessed Kaplan–Meier analysis. Secondary endpoints included overall analysis prognostic...
Abstract Introduction EndoPredict (EP) is an RNA-based multigene test that predicts the likelihood of distant recurrence in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) breast cancer (BC) who are being treated adjuvant endocrine therapy. Herein we report prospective-retrospective clinical validation EP node-positive, chemotherapy-treated, ER+/HER2− BC GEICAM 9906 trial. Methods The ( N = 1,246) were either six cycles fluorouracil,...
To identify a group of patients who might benefit from the addition weekly paclitaxel to conventional anthracycline-containing chemotherapy as adjuvant therapy node-positive operable breast cancer. The predictive value PAM50 subtypes and 11-gene proliferation score contained within assay were evaluated in 820 GEICAM/9906 randomized phase III trial comparing FEC followed by (FEC-P). Multivariable Cox regression analyses secondary endpoint overall survival (OS) performed determine significance...
Pain is a highly prevalent symptom in patients with cancer. Despite therapeutic advances and well-accepted treatment guidelines, percentage of pain are under-treated. Currently, it has been recognized that several barriers management still exist and, addition, there new challenges surrounding complex subtypes pain, such as breakthrough neuropathic requiring further reviews recommendations. This an update the guide our society previously published represents continued commitment SEOM to move...
Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 adjuvant trial to investigate the integration of capecitabine into a regimen epirubicin and docetaxel for node-positive early BC.Patients with operable BC (T1-3/N1-3) were eligible. After surgery, 1,384 patients randomly assigned receive plus cyclophosphamide (EC; 90 600 mg/m(2), respectively, × four cycles), followed by (100 mg/m(2) cycles; EC-T) or (ET; 75 (1,250 twice day on days 1 14, ET-X); all regimens...
Adding taxanes to anthracycline-based adjuvant therapy improves survival outcomes of patients with node-positive breast cancer (BC). Currently, however, most BC are node negative at diagnosis. The only pure node-negative study (Spanish Breast Cancer Research Group 9805) reported so far showed a docetaxel benefit but significant toxicity. Here we tested the efficacy and safety weekly paclitaxel (wP) in patients, which is yet be established.Patients having T1-T3/N0 tumors least one high-risk...
Abstract Background Neoadjuvant treatment is increasingly one of the preferred therapeutic options for early breast cancer and may have some unique outcomes, such as identifying predictive prognostic factors response or increasing knowledge individual tumor biology. Design A panel experts from different specialties reviewed published clinical studies on neoadjuvant management cancer. Recommendations were made that emphasized multidisciplinary investigational leverage in Results therapy has...
Bone metastases are common in many advanced solid tumours, being breast, prostate, thyroid, lung, and renal cancer the most prevalent. can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord compression, need of bone irradiation or surgery, hypercalcaemia. Patients with experience pain, functional impairment have a negative impact on their quality life. Several imaging techniques available for diagnosis this disease. Bone-targeted therapies include...
We comparatively evaluated different cytokeratin (CK) reagents analyzed by flow cytometry (FCM) for the identification of best combination DNA/CK staining detecting minimal numbers breast cancer cells in peripheral blood (PB). In 59 primary tumors, we reactivity up to 6 anti-CK using multiparameter FCM: anti-CK7, anti-CK20, anti–pan-CK, anti-CK8/CK18, anti-CK8, and anti-CK18. Afterward, dilutional experiments Michigan Cancer Foundation (MCF)7 PB were performed, sensitivity a DNA/CK18 was evaluated.
Abstract Purpose: To determine the recommended dose, cardiac safety, and antitumor activity of nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, anti-HER-2 monoclonal antibody trastuzumab in patients with HER-2-overexpressing locally advanced nonoperable breast cancer (LABC) metastatic (MBC). Experimental Design: Women measurable, previously untreated, LABC MBC a baseline left ventricular ejection fraction (LVEF) >50% received weekly combination escalating doses paclitaxel...
There are several prognostic multigene-based tests for managing breast cancer (BC), but limited data comparing them in the same cohort. We compared performance of EndoPredict (EP) test (standardized pathology laboratory) with research-based PAM50 non-standardized qRT-PCR assay node-positive estrogen receptor-positive (ER+) and HER2-negative (HER2−) BC patients receiving adjuvant chemotherapy followed by endocrine therapy (ET) GEICAM/9906 trial. EP risk recurrence (ROR) scores [based on...
Abstract There is growing evidence about how physical activity can improve cancer care. Unfortunately, exercise still not widely prescribed to oncology patients, despite the benefit it brings. For this occur, necessary for a multidisciplinary approach involving different types of healthcare professionals, given that each treatment be tailored single case. Besides incorporating appropriate infrastructures and referral pathways, we need integrate into practice, which ameliorates patients’...
Human epidermal growth factor receptor 2 (HER-2) overexpression has been associated with the genesis and progression of a subset breast cancers. The function HER-2 may be upregulated by or availability neuregulins (NRGs), group transmembrane factors. Transmembrane NRGs strongly activated cell proliferation in cancer cells that did not overexpress HER-2, treatment trastuzumab prevented proliferative action NRG. This raised relevant clinical question whether patients considered as negative,...
Recently, it has been suggested that C2ORF40 is a candidate tumor suppressor gene in breast cancer. However, the mechanism for reduced expression of and its functional role cancers remain unclear. Here we show frequently silenced human primary cell lines through promoter hypermethylation. mRNA level significantly associated with patient disease-free survival distant cancer metastasis. Overexpression inhibits proliferation, migration invasion. By contrast, silencing promotes these biological...
The purpose of this article was to provide updated recommendations for the diagnosis and treatment renal cell carcinoma. Pathological confirmation is mandatory before with ablative or focal therapies any type systemic therapy. Renal cancer should be staged according TNM classification system. A laparoscopic nephron-sparing surgery approach tumors <4 cm if technically feasible. Otherwise, radical (or partial in selected cases) nephrectomy choice, lymph node dissection only performed patients...
The PEARL study showed that palbociclib plus endocrine therapy (palbociclib/ET) was not superior to capecitabine in improving progression-free survival postmenopausal patients with metastatic breast cancer resistant aromatase inhibitors, but better tolerated. This analysis compared patient-reported outcomes.The quality of life (QoL) population comprised 537 patients, 268 randomised palbociclib/ET (exemestane or fulvestrant) and 269 capecitabine. Patients completed the European Organisation...
Breast cancer is a major public health problem. Despite remarkable advances in early diagnosis and treatment, one three women may have metastases since diagnosis. Better understanding of prognostic predictive factors allows us to select the most appropriate adjuvant therapy each patient. In these guidelines, we summarize current evidence for medical management early-stage breast cancer.